과제정보
The CYP2D6 genotyping was performed as part of the other study approved by ethical committees of each hospital (Asan Medical Center: 2018-0650, Dongguk University Ilsan Hospital: 2019-08-004-002).
참고문헌
- Chai JY. History and current status of malaria in Korea. Infect Chemother 2020; 52: 441-452. https://doi.org/10.3947/ic.2020.52.3.441
- Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, Luong TL, Bandara Herath HM, Dhammika Nanayakkara NP, Tekwani BL, Walker LA, Nolan CK, Sciotti RJ, Zottig VE, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Marcsisin SR. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother 2015; 59: 2380-2387. https://doi.org/10.1128/AAC.00015-15
- Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. Pharmacol Ther 2016; 161: 1-10. https://doi.org/10.1016/j.pharmthera.2016.03.011
- Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369: 1381-1382. https://doi.org/10.1056/NEJMc1301936
- Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty, Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ, Sutanto I, Sudoyo H, Setiabudy R. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Netw Open 2018; 1: e181449. https://doi.org/10.1001/jamanetworkopen.2018.1449
- Goo YK, Ji SY, Shin HI, Moon JH, Cho SH, Lee WJ, Kim JY. First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. PLoS One 2014; 9: e97390. https://doi.org/10.1371/journal.pone.0097390
- Im JH, Huh K, Yoon CG, Woo H, Lee JS, Chung MH, Klein TA, Jung J. Malaria control and chemoprophylaxis policy in the Republic of Korea Armed Forces for the previous 20 years (1997- 2016). Malar J 2018; 17: 1-9. https://doi.org/10.1186/s12936-018-2449-4
- Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 2005; 4: 20. https://doi.org/10.1186/1475-2875-4-20
- Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin Transl Sci 2020; 13: 116-124. https://doi.org/10.1111/cts.12692
- de Araujo FCF, De Rezende AnM, Fontes CJF, Carvalho LH, de Brito CFAJPo. Multiple-clone activation of hypnozoites is the leading cause of relapse in Plasmodium vivax infection. PLoS One 2012; 7: e49871. https://doi.org/10.1371/journal.pone.0049871
- Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195: 927-933. https://doi.org/10.1086/512241
- Schmidt LH, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 1977; 26: 1116-1128. https://doi.org/10.4269/ajtmh.1977.26.1116
- Mat Salleh NH, Rahman MFA, Samsusah S, De Silva JR, Ng DC, Ghozali AH, Tan JH, Lai MY, Amir A, Liew JWK, Lau YL. Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia. Trans R Soc Trop Med Hyg 2020; 114: 700-703. https://doi.org/10.1093/trstmh/traa042
- Martin Ramirez A, Lombardia Gonzalez C, Soler Maniega T, Gutierrez Liarte A, Domingo Garcia D, Lanza Suarez M, Bernal Fernandez MJ, Rubio JM. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. Malar J 2020; 19: 259. https://doi.org/10.1186/s12936-020-03326-1
- US Food and Drug Administration. Clinical drug interaction studies-Cytochrome P450 enzyme-and transporter-mediated drug interactions guidance for industry, January 2020 [Internet]; [cited 2020 June 5]. Available from: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/clinical-druginteraction-studies-cytochrome-p450-enzyme-and-transportermediated-drug-interactions
- Tagariello G, Sartori R, Inojosa WO, Candiotto L, Radossi P, Scarpa E, Tassinari C. Dramatic post-splenectomy onset of malaria caused by latent Plasmodium vivax in a female immigrant with severe immunological anaemia. Blood Transfus 2014; 12: 428-430. https://doi.org/10.2450/2014.0242-13
- Kho S, Andries B, Poespoprodjo JR, Commons RJ, Shanti PAI, Kenangalem E, Douglas NM, Simpson JA, Sugiarto P, Anstey NM, Price RN. High risk of Plasmodium vivax malaria following splenectomy in Papua, Indonesia. Clin Infect Dis 2019; 68: 51-60. https://doi.org/10.1093/cid/ciy403